These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9339266)

  • 1. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease.
    Cummings JL
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S1-9. PubMed ID: 9339266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.
    Cummings JL; Masterman DL
    J Clin Psychiatry; 1998; 59 Suppl 13():23-30. PubMed ID: 9771827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type.
    Pinto T; Lanctôt KL; Herrmann N
    Ageing Res Rev; 2011 Sep; 10(4):404-12. PubMed ID: 21292041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.
    Levy ML; Cummings JL; Kahn-Rose R
    Gerontology; 1999; 45 Suppl 1():15-22. PubMed ID: 9876214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients.
    Shimabukuro J; Awata S; Matsuoka H
    Psychiatry Clin Neurosci; 2005 Jun; 59(3):274-9. PubMed ID: 15896220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia.
    Srikanth S; Nagaraja AV; Ratnavalli E
    J Neurol Sci; 2005 Sep; 236(1-2):43-8. PubMed ID: 15964021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic therapies for Alzheimer's disease: progress and prospects.
    Palmer AM
    Curr Opin Investig Drugs; 2003 Jul; 4(7):820-5. PubMed ID: 14619403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychiatric symptoms predict change in quality of life of Alzheimer disease patients: a two-year follow-up study.
    Tatsumi H; Nakaaki S; Torii K; Shinagawa Y; Watanabe N; Murata Y; Sato J; Mimura M; Furukawa TA
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):374-84. PubMed ID: 19566770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral outcomes in clinical trials for Alzheimer disease.
    Ferris SH; Mackell JA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.
    Wynn ZJ; Cummings JL
    Dement Geriatr Cogn Disord; 2004; 17(1-2):100-8. PubMed ID: 14564129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Depression and frontal dysfunction: risks for the elderly?].
    Thomas P; Hazif Thomas C; Billon R; Peix R; Faugeron P; Clément JP
    Encephale; 2009 Sep; 35(4):361-9. PubMed ID: 19748373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating patients and caregivers through the course of Alzheimer's disease.
    Aupperle PM
    J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apathy and depression in Alzheimer's disease are associated with functional deficit and psychotropic prescription.
    Benoit M; Andrieu S; Lechowski L; Gillette-Guyonnet S; Robert PH; Vellas B;
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):409-14. PubMed ID: 17918770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
    Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR Study.
    Benoit M; Robert PH; Staccini P; Brocker P; Guerin O; Lechowski L; Vellas B;
    J Nutr Health Aging; 2005; 9(2):95-9. PubMed ID: 15791352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances.
    Harwood DG; Sultzer DL; Wheatley MV
    Neuropsychiatry Neuropsychol Behav Neurol; 2000 Apr; 13(2):83-8. PubMed ID: 10780626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease.
    Cummings JL; Back C
    Am J Geriatr Psychiatry; 1998; 6(2 Suppl 1):S64-78. PubMed ID: 9581223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical heterogeneity: responders to cholinergic therapy.
    Eagger SA; Harvey RJ
    Alzheimer Dis Assoc Disord; 1995; 9 Suppl 2():37-42. PubMed ID: 8534422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.